- Home
- GSHD vs DNTH Comparison
GSHD vs DNTH Comparison
Compare GSHD & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | DNTH |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GSHD | DNTH |
|---|---|---|
| Price | $76.61 | $44.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $94.70 | $68.00 |
| AVG Volume (30 Days) | 292.9K | ★ 780.0K |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.78% | N/A |
| EPS Growth | ★ 68.12 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $353,231,000.00 | $3,078,000.00 |
| Revenue This Year | $16.48 | N/A |
| Revenue Next Year | $20.04 | N/A |
| P/E Ratio | $66.90 | ★ N/A |
| Revenue Growth | ★ 25.01 | N/A |
| 52 Week Low | $64.41 | $13.37 |
| 52 Week High | $127.99 | $45.46 |
Technical Indicators
Market Signals| Indicator | GSHD | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 65.78 |
| Support Level | $74.15 | $42.00 |
| Resistance Level | $77.56 | $45.46 |
| Average True Range (ATR) | 2.29 | 2.00 |
| MACD | 0.81 | 0.13 |
| Stochastic Oscillator | 89.23 | 79.49 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.